Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/8/2017
SIETES contiene 91969 citas

 
 
 1 a 20 de 433 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
2. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
3.Enlace a cita original Cita con resumen
Gorricho J, Garjón J, Alonso A, Celaya MC, Saiz LC, Erviti J, López A. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol 2017:11 de marzo. [Ref.ID 101545]
4. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]
5. Cita con resumen
Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]
6.Enlace a cita original Cita con resumen
Ariz MJ, Elizondo G. Nuevos antidiabéticos. ¿Qué lugar deben ocupar en terapéutica?. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-8. [Ref.ID 101436]
7. Cita con resumen
Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]
8.Enlace a cita original Cita con resumen
Wang R, Kim BV, van Wely M, Johnson NP, Costello MF, Zhang H, Ng EHY, Legro RS, Bhattacharya S, Norman RJ, Mol BWJ. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ 2017;356:j138. [Ref.ID 101407]
9. Cita con resumen
Anónimo. Drugs for type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18. [Ref.ID 101372]
10. Cita con resumen
Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]
11. Cita con resumen
Anónimo. Metformin for prediabetes. Med Lett Drugs Ther 2016;58:141. [Ref.ID 100945]
12. Cita con resumen
Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]
13. Cita con resumen
Anónimo. Diarrhées d'origine médicamenteuse. Prescrire 2016;36:748-55. [Ref.ID 100894]
15. Cita con resumen
van Dalem J, Brouwers MCGJ, Stehouwer CDA, Krings A, Leufkens HGM, Driessen JHM, de Vries F, Burden AM. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ 2016;354:i3625. [Ref.ID 100570]
16. Cita con resumen
Butler PC. Glucagon-like peptide 1 drugs a second-line therapy for type 2 diabetes . JAMA Intern Med 2016;176:octubre. [Ref.ID 100561]
17. Cita con resumen
Anónimo. Empagliflozine. Prescrire 2016;36:168-73. [Ref.ID 100524]
18.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
19. Cita con resumen
Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SB, Cho Y, Nadeau-Fredette A-C, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GFM. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 2016;316:313-24. [Ref.ID 100498]
20. Cita con resumen
Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suárez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740-51. [Ref.ID 100415]
Seleccionar todas
 
 1 a 20 de 433 siguiente >>